Comorbid mental disorders in patients with schizophrenia;Komorbide psychische störungen bei schizophrenie

PsychoNeuro

Volumn 32, Issue 7-8, 2006, Pages 372-378

  Huber, Christian G ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL DECANOATE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZOTEPINE;

BEHAVIOR THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DOSE RESPONSE; DYSKINESIA; HEALTH CARE COST; HUMAN; MENTAL DISEASE; META ANALYSIS; MORBIDITY; MORTALITY; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SCHIZOPHRENIA; SOCIAL PHOBIA; SYSTEMATIC REVIEW;

EID: 33749997711     PISSN: 16119991     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951442     Document Type: Review

References (75)

1. Addington D, Addington J et al. A depression rating scale for schizophrenics. Schizophr Res 1990; 3 (4): 247-51
2. Adler LE, Griffith JM. Concurrent medical illness in the schizophrenic patient. Epidemiology, diagnosis, and management. Schizophr Res 1991; 4 (2): 91-107
3. Arndt S, Tyrrell G et al. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med 1992; 22 (2): 379-88
4. Baynes D, Mulholland C et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 2000; 45 (1-2): 47-56
5. Bechdolf A, Pohlmann B et al. Motivational interviewing for patients with comorbid schizophrenia and substance abuse disorders: a review. Fortschr Neurol Psychiatr 2005; 73 (12): 728-35
6. Bersani G, Orlandi V et al. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252 (2): 86-92
7. Blanchard JJ, Brown SA et al. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 2000; 20 (2): 207-34
8. Braga RJ, Petrides G et al. Anxiety disorders in schizophrenia. Compr Psychiatry 2004; 45 (6): 460-8
9. Dickey B, Azeni H: Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 1996; 86 (7): 973-7
10. Dixon L, Postrado L et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999; 187 (8): 496-502
11. Fenton WS, McGlashan TH: The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1986; 143 (4): 437-41
12. Gaebel W, Falkai P. Behandlungsleitlinie Schizophrenie. Darmstadt, Steinkopff, 2005
13. Gearon JS, Kaltman SI et al. Traumatic life events and PTSD among women with substance use disorders and schizophrenia. Psychiatr Serv 2003; 54 (4): 523-8
14. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60 Suppl 21: 10-5
15. Goodman WK, Price LH et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46 (11): 1006-11
16. Goodwin RD, Amador XF et al. Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res 2003; 61 (1): 89-95
17. Gouzoulis-Mayfrank E. Dual diagnosis of psychosis and addiction. From principles to practice. Nervenarzt 2004; 75 (7): 642-50
18. Green AI, Canuso CM et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003; 26 (1): 115-39
19. Hamilton MC, Guy W. Hamilton depression scale [HAMD], in ECDEU assessment manual for psychopharmacology. Edited by U.S. National Institute of Health PRB. Rockville, MD, 1967, 179-92
20. Harrow M, Yonan CA et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994; 20 (2): 327-38
21. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 2002; 106 (2): 83-96
22. Hawton K, Sutton L et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 9-20
23. Heila H, Isometsa ET et al. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997; 154 (9): 1235-42
24. Helmchen H, Hippius H. Depression syndrome in the course of neuroleptic therapy. Nervenarzt 1967; 38 (10): 455-8
25. House A, Bostock J et al. Depressive syndromes in the year following onset of a first schizophrenic illness*. Br J Psychiatry 1987; 151: 773-9
26. Hughes JR, Hatsukami DK et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143 (8): 993-7
27. Hwang MY, Morgan JE et al. Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci 2000; 12 (1): 91-4
28. Keshavan MS, Duggal HS et al. Personality dimensions in first-episode psychoses. Am J Psychiatry 2005; 162 (1): 102-9
29. Kessler RC, Stang P et al. Lifetime comorbidities between social phobia and mood disorders in the US National Comorbidity Survey. Psychol Med 1999; 29 (3): 555-67
30. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142 (11): 1259-64
31. Kim-Cohen J, Caspi A et al. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry 2003; 60 (7): 709-17
32. Kingsbury SJ, Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hosp Community Psychiatry 1990; 41 (2): 133-4
33. Knights A, Hirsch SR. "Revealed" Depression and drug treatment for schizophrenia. Arch Gen Psychiatry 1981; 38 (7): 806-11
34. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1994; 151(11): 1714-5
35. Koreen AR, Siris SG et al. Depression in first-episode schizophrenia. Am J Psychiatry 1993; 150 (11): 1643-8
36. Kovasznay B, Fleischer J et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23(2): 195-201
37. Lambert M, Conus P et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112 (2): 141-8
38. Lambert M, Haasen C et al. Consumption patterns and motivation for use of addictive drugs in schizophrenic patients. Psychiatr Prax 1997; 24 (4): 185-9
39. Lonnqvist JK, Henriksson MM et al. Mental disorders and suicide prevention. Psychiatry Clin Neurosci 1995; 49 Suppl 1: S 111-6
40. Mandel MR, Severe JB et al. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1982; 39 (2): 197-203
41. Martin RL, Cloninger CR et al. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985; 46 (11 Pt 2): 9-13
42. McDougle CJ, Epperson CN et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57 (8): 794-801
43. McGlashan TH, Carpenter WT Jr. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33 (2): 231-9
44. McGorry PD, Chanen A et al. Posttraumatic stress disorder following recent-onset psychosis. An unrecognized postpsychotic syndrome. J Nerv Ment Dis 1991; 179 (5): 253-8
45. Mendlowicz MV, Braga RJ et al. Comorbidity and disability in outpatients with schizophrenia. Am J Psychiatry 2005; 162 (2): 400; author reply 400-1
46. Moran P, Hodgins S. The correlates of comorbid antisocial personality disorder in schizophrenia. Schizophr Bull 2004; 30 (4): 791-802
47. Morrison D, Clark D et al. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry 1998; 155 (6): 855
48. Mueser KT, Drake RE et al. Dual diagnosis: a review of etiological theories. Addict Behav 1998; 23 (6): 717-34
49. Mueser KT, Yarnold PR et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 1990; 16 (1): 31-56
50. Muller JE, Koen L et al. Anxiety disorders and schizophrenia. Curr Psychiatry Rep 2004; 6 (4): 255-61
51. Naber D. Treatment of drug dependent patients in a general hospital. Internist (Berl) 1994; 35 (9): 858-62
52. Nechmad A, Ratzoni G et al. Obsessive-compulsive disorder in adolescent schizophrenia patients. Am J Psychiatry 2003; 160 (5): 1002-4
53. Ongur D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 2005; 75 (2-3): 349-62
54. Owen C, Rutherford V et al. Noncompliance in psychiatric aftercare. Community Ment Health J 1997; 33 (1): 25-34
55. Pallanti S, Quercioli L et al. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry 2004; 161 (1): 53-8
56. Perenyi A, Norman T et al. Negative symptoms, depression, and parkinsonian symptoms in chronic, hospitalised schizophrenic patients. J Affect Disord 1998; 48 (2-3): 163-9
57. Perkins D, Lieberman J et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185: 18-24
58. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166 (6): 712-26; discussion 727-33
59. Poyurovsky M, Dorfman-Etrog P et al. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. Int Clin Psychopharmacol 2000; 15 (3): 169-73
60. Poyurovsky M, Fuchs C et al. Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry 1999; 156 (12): 1998-2000
61. Read J, Agar K et al. Sexual and physical abuse during childhood and adulthood as predictors of hallucinations, delusions and thought disorder. Psychol Psychother 2003; 76 (Pt 1): 1-22
62. Read J, van Os J et al. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatr Scand 2005; 112 (5): 330-50
63. Regier DA, Farmer ME et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Jama 1990; 264 (19): 2511-8
64. Schafer I, Harfst T et al. Childhood trauma and dissociation in female patients with schizophrenia spectrum disorders: an exploratory study. J Nerv Ment Dis 2006; 194(2): 135-8
65. Scheller-Gilkey G, Moynes K et al. Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res 2004; 69(2-3): 167-74
66. Schimmelmann BG, Conus P et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005; 66 (10): 1239-46
67. Schonfeld WH, Verboncoeur CJ et al. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord 1997; 43 (2): 105-19
68. Sevy S, Robinson DG et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104 (5): 367-74
69. Sim K, Mahendran R et al. Health-related quality of life and psychiatric comorbidity in first episode psychosis. Compr Psychiatry 2005; 46 (4): 278-83
70. Sim K, Swapna V et al. Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Program (EPIP) experience. Acta Psychiatr Scand 2004; 109 (1): 23-9
71. Siris SG: Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991; 17(1): 75-98
72. Siris SG, Addington D et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res 2001; 47 (2-3): 185-97
73. Taiminen TJ, Kujari H: Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. Acta Psychiatr Scand 1994; 90 (4): 247-51
74. Tollefson GD, Sanger TM et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55 (3): 250-8
75. Wassink TH, Flaum M et al. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry 1999; 156 (2): 315-6